| CAS NO: | 35482-50-9 |
| 包装 | 价格(元) |
| 5mg (solution) | 电议 |
| 10mg (solution) | 电议 |
| Physical Appearance | A solution in acetate. To change the solvent, simply evaporate the acetate containing under a gentle stream of nitrogen and immediately add the solvent of choice. |
| Storage | Store at -20°C |
| M.Wt | 258.4 |
| Cas No. | 35482-50-9 |
| Formula | C17H22O2 |
| Solubility | ≤30mg/ml in ethanol;30mg/ml in DMSO;30mg/ml in dimethyl formamide |
| Chemical Name | 5-methyl-2-[(1R,6R)-3-methyl-6-(1-methylethenyl)-2-cyclohexen-1-yl]-1,3-benzenediol |
| Canonical SMILES | CC1=C[C@@H](C2=C(O)C=C(C)C=C2O)[C@H](C(C)=C)CC1 |
| 运输条件 | 蓝冰运输或根据您的需求运输。 |
| 一般建议 | 为了使其更好的溶解，请用37℃加热试管并在超声波水浴中震动片刻。不同厂家不同批次产品溶解度各有差异，仅做参考。若实验所需浓度过大至产品溶解极限，请添加助溶剂助溶或自行调整浓度。溶液形式一般不宜长期储存，请尽快用完。 |
O-1821 is an cannabidiol analog with similar structure to O-1918, a selective antagonist of abnormal cannabidiol.
Abnormal cannabidiol, a synthetic regioisomer of cannabidiol, fails to elicit either central cannabinoid (CB1) or peripheral cannabinoid (CB2) receptors and is lack of psychotropic activity. It can induce endothelium-dependent vasodilation through a CB1/CB2/nitric oxide-independent mechanism.
In vitro: O-1821 is a cannabidiol analog with similar structure to O-1918, which was identified as a selective antagonist of abnormal cannabidiol at the non-central cannabinoid (CB1)/peripheral cannabinoid (CB2) receptors endothelial receptor. It was found that O-1918 could not bind to CB1 or CB2 receptors and thus could not cause vasorelaxation at concentrations up to 30 μM, but it could cause concentration-dependent inhibition of the vasorelaxant effects of abn-cbd and anandamide. Moreover, in human umbilical vein endothelial cells, abn-cbd was able to induce phosphorylation of p42/44 mitogenactivated protein kinase and protein kinase B/Akt, which could be inhibited by O-1918 or by phosphatidylinositol 3 (PI3) kinase inhibitors [1].
In vivo: O-1918 was found to be able to inhibit the hypotensive effect of abn-cbd dose-dependently but not the hypotensive effect of the CB1 receptor agonist (-)-11-OH-Δ9-tetrahydrocannabinol dimethylheptyl in anesthetized mice [1].
Clinical trial: So far, no clinical study has been conducted.
Reference:
[1] Offertáler, L. ,Mo, F.M.,Bátkai, S., et al. Selective ligands and cellular effectors of a G protein-coupled endothelial cannabinoid receptor. Molecular Pharmacology 63(3), 699-705 (2003).
m.cnreagent.com